These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia. McGregor BA; Brown AW; Osswald MB; Savona MR Am J Hematol; 2009 Apr; 84(4):228-30. PubMed ID: 19260120 [TBL] [Abstract][Full Text] [Related]
23. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. Abou Dalle I; Kantarjian HM; Short NJ; Konopleva M; Jain N; Garcia-Manero G; Garris R; Qiao W; Cortes JE; O'Brien S; Kebriaei P; Kadia T; Jabbour E; Ravandi F Am J Hematol; 2019 Dec; 94(12):1388-1395. PubMed ID: 31595534 [TBL] [Abstract][Full Text] [Related]
24. Safety and effectiveness of clofarabine in Japanese patients with relapsed/refractory acute lymphoblastic leukaemia: a post-marketing surveillance study. Kazama H; Nishina S; Seto T Jpn J Clin Oncol; 2024 Jul; 54(7):778-786. PubMed ID: 38643356 [TBL] [Abstract][Full Text] [Related]
25. Clofarabine: a size that fits all, may not fit all. Vij R Leuk Lymphoma; 2009 Mar; 50(3):309-10. PubMed ID: 19347718 [No Abstract] [Full Text] [Related]
26. Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol. Bassan R; Fumagalli M; Chiaretti S; Audisio E; Cascavilla N; Paolini S; Delia M; Cerqui E; Micò C; Fabbiano F; Canichella M; Scattolin AM; Perfetti P; Paoloni F; Iodice M; Vitale A; Della Starza I; Fazi P; Vignetti M; Foà R Leuk Lymphoma; 2019 Dec; 60(14):3482-3492. PubMed ID: 31298059 [TBL] [Abstract][Full Text] [Related]
27. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia. Steinherz PG; Shukla N; Kobos R; Steinherz L Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253 [TBL] [Abstract][Full Text] [Related]
28. Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan. Koh K; Ogawa C; Okamoto Y; Kudo K; Inagaki J; Morimoto T; Mizukami H; Ecstein-Fraisse E; Kikuta A Int J Hematol; 2016 Aug; 104(2):245-55. PubMed ID: 27086352 [TBL] [Abstract][Full Text] [Related]
29. The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: a case report. Gidwani P; Ramesh KH; Liu Y; Kolb EA Chemotherapy; 2008; 54(2):120-4. PubMed ID: 18303261 [TBL] [Abstract][Full Text] [Related]
30. Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia. Carraway HE; Sawalha Y; Gojo I; Lee MJ; Lee S; Tomita Y; Yuno A; Greer J; Smith BD; Pratz KW; Levis MJ; Gore SD; Ghosh N; Dezern A; Blackford AL; Baer MR; Gore L; Piekarz R; Trepel JB; Karp JE Leuk Res; 2021 Nov; 110():106707. PubMed ID: 34563945 [TBL] [Abstract][Full Text] [Related]
31. Clofarabine in pediatric acute leukemia: current findings and issues. Hijiya N; Barry E; Arceci RJ Pediatr Blood Cancer; 2012 Sep; 59(3):417-22. PubMed ID: 22354543 [TBL] [Abstract][Full Text] [Related]
32. Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Advani AS; Gundacker HM; Sala-Torra O; Radich JP; Lai R; Slovak ML; Lancet JE; Coutre SE; Stuart RK; Mims MP; Stiff PJ; Appelbaum FR Br J Haematol; 2010 Dec; 151(5):430-4. PubMed ID: 21113977 [TBL] [Abstract][Full Text] [Related]
33. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Jabbour E; Kantarjian H; Ravandi F; Thomas D; Huang X; Faderl S; Pemmaraju N; Daver N; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Yin CC; Khoury JD; Jorgensen J; Estrov Z; Bohannan Z; Konopleva M; Kadia T; Jain N; DiNardo C; Wierda W; Jeanis V; O'Brien S Lancet Oncol; 2015 Nov; 16(15):1547-1555. PubMed ID: 26432046 [TBL] [Abstract][Full Text] [Related]
34. Infections in relapsed or refractory acute myeloid leukemia patients given clofarabine+cytarabine. Knoebel RW; McQuary A; Becker P; Hendrie P; Petersdorf S; Appelbaum FR; Estey E Leuk Res; 2011 Sep; 35(9):e164-6. PubMed ID: 21684006 [No Abstract] [Full Text] [Related]
35. Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia. Shukla N; Kobos R; Renaud T; Steinherz LJ; Steinherz PG Pediatr Blood Cancer; 2014 Mar; 61(3):431-5. PubMed ID: 24115731 [TBL] [Abstract][Full Text] [Related]
36. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant. Samra B; Kantarjian HM; Sasaki K; Alotaibi AS; Konopleva M; O'Brien S; Ferrajoli A; Garris R; Nunez CA; Kadia TM; Short NJ; Jabbour E Acta Haematol; 2021; 144(3):285-292. PubMed ID: 33238261 [TBL] [Abstract][Full Text] [Related]
37. Clofarabine. Pui CH; Jeha S Nat Rev Drug Discov; 2005 May; Suppl():S12-3. PubMed ID: 15962525 [TBL] [Abstract][Full Text] [Related]
38. Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse. Balsat M; Cacheux V; Carre M; Tavernier-Tardy E; Thomas X Expert Rev Anticancer Ther; 2020 Oct; 20(10):879-891. PubMed ID: 33016157 [TBL] [Abstract][Full Text] [Related]